Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Clinical stage biotechnology company Aphios has obtained notification of allowance (NOA) from the US Patent and Trademark Office (USPTO) for its patent application for oral delivery of insulin.
Subscribe to our email newsletter
The patent entitled ‘ Polymer Microspheres/Nanospheres and Encapsulating Therapeutic Proteins Therein’ covers the company’s oral delivery nanotechnology, designed for improving the oral bioavailability of macromolecules like insulin.
Aphios president and CEO Trevor Castor said, "Aphios is enhancing the oral bioavailability of therapeutic proteins by encapsulating protein macromolecules and nanoparticles in biodegradable polymer nanospheres."
The entrapped therapeutic proteins in nanospheres get mobilized in the gut and transported to the systemic circulation by the epithelial cells, claims the company.
The company said the nanoparticles technology is applicable to large as well small protein molecules, independent of size and molecular weight.